Haemonetics Corporation, a global medical technology firm dedicated to innovative solutions that enhance patient outcomes, announced the publication of a study offering fresh support for the safety and efficacy of its VASCADE MVP XL venous vascular closure system in procedures involving large-bore sheaths. This retrospective cohort analysis marks the largest reported group evaluated with the VASCADE MVP XL system so far.

Performed at Emory University with funding from Haemonetics, the single-center review by an experienced operator assessed real-world results in 1,623 patients treated with the VASCADE MVP XL system after large-bore venous access electrophysiology procedures up to 17F outer diameter. These included pulsed field ablation for atrial fibrillation, left atrial appendage closure, and combined interventions. Key findings showed quick hemostasis with a median of two minutes, a 92.5 percent same-day discharge rate at a median of 3.5 hours, and a solid safety record with only 1.2 percent overall vascular complications and no need for surgical intervention.

Ken Crowley, Vice President and General Manager of Interventional Technologies at Haemonetics, noted that ongoing real-world evidence from a sizable and varied patient group continues to highlight the consistent results of the VASCADE MVP XL system in large-bore venous closure. He added that as clinicians look for advanced closure options to boost outcomes and experiences in pulsed field ablation, left atrial appendage closure, and related procedures, the system offers electrophysiology teams a dependable approach for fast hemostasis and same-day discharge.

Corresponding author David B. De Lurgio, M.D., Medical Director of Electrophysiology at Emory Saint Joseph's Hospital and professor at Emory University School of Medicine, observed that same-day discharge was reliably achieved even with larger sheaths than those typically used in device-based closure. With more than 1,600 patients in the cohort, the data supply additional practical insights across diverse cases, including those with greater comorbidities in left atrial appendage closure and combined procedures.

In March 2026 the U.S. Food and Drug Administration approved expanded labeling for the VASCADE MVP XL system to cover procedures with 10-14F inner diameter and up to 17F outer diameter sheaths. The system is cleared for closure after use of leading pulsed field ablation technologies and left atrial appendage closure solutions. Approval drew on results from the AMBULATE EXPAND trial, which showed rapid hemostasis without complications and enabled same-day discharge. VASCADE MVP XL remains the sole extravascular venous closure system with clinical proof in electrophysiology procedures using up to 17F outer diameter sheaths.

Haemonetics is a global medical technology company committed to raising the quality, effectiveness, and efficiency of health care through its Apheresis and MedSurg businesses, including advanced vascular closure systems.

Statements in this release that are not historical facts may represent forward-looking statements. These are based on current projections and are subject to risks and uncertainties that could cause actual results to differ materially. Haemonetics does not plan to update these statements.